Status | Study |
Not yet recruiting |
Study Name: Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Condition: Adrenal Cortex Carcinoma Adult Alveolar Soft Part Sarcoma Date: 2016-08-15 Interventions: Drug: Cabozantinib S-malate Gi |
Not yet recruiting |
Study Name: Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Condition: Functional Pancreatic Neuroendocrine Tumor Malignant Somatostatinoma Date: 2016-07-10 Interventions: Drug: Capecitabine Given PO |
Recruiting |
Study Name: A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Condition: Malignant Rhabdoid Tumors (MRT) Rhabdoid Tumors of the Kidney (RTK) Date: 2015-10-21 Interventions: Drug: Tazemetostat Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine |
Recruiting |
Study Name: Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer Condition: Breast Cancer Colon Cancer Extrahepatic Bile Duct Cancer Date: 2014-10-09 Interventions: Procedure: radionuclide imaging |
Recruiting |
Study Name: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Condition: Carcinoma of the Collecting Ducts of Bellini Chromophobe Renal Cell Carcinoma Date: 2013-01-10 Interventions: Drug: Pazopanib Hydrochloride Given PO Other Names: |
Active, not recruiting |
Study Name: Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Condition: Childhood Solid Neoplasm Childhood Thyroid Gland Medullary Carcinoma Date: 2012-10-16 Interventions: Drug: Cabozantinib S-malate Gi |
Completed |
Study Name: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Condition: Gastrin-Producing Neuroendocrine Tumor Lung Carcinoid Tumor Date: 2010-09-16 Interventions: Biological: Cixutumumab Given |
Completed |
Study Name: Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Condition: Extensive Stage Small Cell Lung Cancer Hereditary Paraganglioma Date: 2010-06-30 Interventions: Drug: temsirolimus Given IV |
Active, not recruiting |
Study Name: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Condition: Gastrinoma Glucagonoma Insulinoma Date: 2008-04-09 Interventions: Drug: everolimus Given orally |
Terminated |
Study Name: Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer Condition: Thyroid Neoplasm Thyroid Carcinoma M Date: 2008-03-26 Interventions: Other: 18F-L-DOPA PET PET performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA |